I work in the Policy and Campaigns team at Breast Cancer Now.
As you may be aware the National Institute for Health and Care Excellence (NICE) is currently assessing olaparib (also known as Lynparza) to see whether it can be made available on the NHS for the adjuvant treatment of high-risk, HER2-negative, BRCA positive primary breast cancer.
We're currently gathering evidence and insights to help inform our response to the assessment of this treatment. As part of this we would like to hear from anybody who has received the treatment, whether through the clinical trial or an early access scheme.
If you are able to help, please complete this short form by 25th March https://breastcancernow.org/about-us/tell-us-your-story or email email@example.com
Your views will be shared with NICE anonymously.
With best wishes,